Search Results - "Siu, L.L."

Prioritizing targets for precision cancer medicine by Andre, F., Mardis, E., Salm, M., Soria, J.-C., Siu, L.L., Swanton, C.

“…The implementation of cancer genomic testing into the clinical setting has brought major opportunities. However, as our understanding of cancer initiation,…”
Get full text

Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription by Brana, I, Siu, L L

“…Despite the policy changes to decrease tobacco consumption and therapeutic advances in this disease, squamous cell carcinomas arising from the head and neck…”
Get full text

A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC by Chau, N.G., Hotte, S.J., Chen, E.X., Chin, S.F., Turner, S., Wang, L., Siu, L.L.

“…Vascular endothelial growth factor (VEGF) and c-kit are highly expressed in adenoid cystic carcinoma (ACC) and associated with biologic aggressiveness. This…”
Get full text

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors by Chen, T.W., Razak, A.R., Bedard, P.L., Siu, L.L., Hansen, A.R.

Get full text

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study by Rothenberg, M.L., Cox, J.V., Butts, C., Navarro, M., Bang, Y.-J., Goel, R., Gollins, S., Siu, L.L., Laguerre, S., Cunningham, D.

“…To demonstrate the noninferiority of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX-4) as second-line therapy…”
Get full text

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC) by Spreafico, A, Oza, A.M, Clarke, B.A, Mackay, H.J, Shaw, P, Butler, M, Dhani, N.C, Lheureux, S, Wilson, M.K, Welch, S, Zhang, T, Yu, C, Stockley, T, Siu, L.L, Kamel-Reid, S, Bedard, P.L

“…Abstract Background Genomic alterations that activate the MAPK signaling pathway frequently occur in Type I Epithelial Ovarian Cancers (EOCs). We evaluated…”
Get full text

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients by Rodriguez-Freixinos, V., Lheureux, S., Mandilaras, V., Clarke, B., Dhani, N.C., Mackay, H., Butler, M.O., Wang, L., Siu, L.L., Kamel-Reid, S., Stockley, T., Bedard, P.L., Oza, A.M.

“…Conducting clinical trials in rare malignancies is challenging due to the limited number of patients and differences in biologic behavior. We investigated the…”
Get full text

237 Impact of phase 1 expansion cohorts on probability of success in phase 2 and time-to-drug-approval: analysis of 385 new drugs in oncology by Bugano, D, Hess, K, Siu, L.L, Meric-Bernstam, F, Razak, A.R.A, Hong, D.S

Get full text

2863 A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer by Oosting, S.F, Chen, T.W.W, Huang, S.H.H, Wang, L, Waldron, J, Gilbert, R, Goldstein, D.P, Halmos, G.B, Witjes, M.J.H, Gietema, J.A, O'Sullivan, B, Langendijk, J.A, Siu, L.L, Hansen, A.R

Get full text

Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx by Loong, H.H, Winquist, E, Waldron, J, Chen, E.X, Kim, J, Palma, D, Read, N, Razak, A.R.A, Diaz-Padilla, I, Chan, K, Bayley, A, Hossain, M, Wang, L, Chin, S, Siu, L.L, Hope, A

“…Abstract Background Induction chemotherapy followed by concurrent chemoradiation (CRT) (sequential therapy) has been evaluated in the treatment of…”
Get full text

502 Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028 by O'Neil, B.H, Wallmark, J, Lorente, D, Elez, E, Raimbourg, J, Gomez-Roca, C, Ejadi, S, Piha-Paul, S.A, Moss, R.A, Siu, L.L, Dotti, K, Santoro, A, Gould, M, Yuan, S.S, Koshiji, M, Han, S.W

Get full text

508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041) by Chiu, J.W, Hotte, S.J, Kollmannsberger, C.K, Renouf, D.J, Cescon, D.W, Hedley, D, Chow, S, Moscow, J, Perry, M, Diaz-Padilla, I, Tan, D, Hirte, H, McWhirter, E, Chen, H, Siu, L.L, Bedard, P.L

Get full text

29 A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors by Lassen, U, Schellens, J.H.M, Siu, L.L, Jonker, D.J, Sorensen, M, Jarutat, T, Wang, K, Geho, D, DeMario, M, Goss, G

Get full text

396 A Phase I, Dose-finding Study of BI 853520, a Potent and Selective Inhibitor of Protein Tyrosine Kinase 2 in Patients with Advanced or Metastatic Solid Tumors by de Jonge, M, Sahebjam, S, Mathijssen, R.H, Razak, A, van der Biessen, D, Pronk, L.C, Schnell, D, Siu, L.L

Get full text

OC-018: De-Intensification Candidate Subgroups in HPV(+) Oropharyngeal Cancer Based on Minimal Risk of Distant Metastasis by O'Sullivan, B, Huang, S.H, Siu, L.L, Waldron, J, Zhao, H, Perez-Ordonez, B, Weinreb, I, Irish, J, Liu, F.F, Xu, W

Get full text

8511 POSTER DISCUSSION Phase I Trial of Albumin-bound Paclitaxel (A), Cisplatin (P) and 5-Fluorouracil (F) as Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy (CRT) With Carboplatin (Cb) in Patients (pts) With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) by ilia, I. Diaz-Pad, Waldron, J, Hope, A, Chen, E.X, Chan, K, Kim, J, O'Sullivan, B, Razak, A.R. Abdul, Chin, S.F, Siu, L.L

Get full text

1210 POSTER Phase 1 Study of MLN9708, an Investigational Proteasome Inhibitor, in Advanced Nonhematologic Malignancies- Updated Results by Smith, P.C, Infante, J.R, Siu, L.L, Sullivan, D, Vlahovic, G, Kauh, J, Blakemore, S.J, Gupta, N, Kalebic, T, Thompson, J.A

Get full text

PP 2 Generation of a panel of “actionable” cancer genes for molecular profiling (MP) in a feasibility study of targeted and genome wide sequencing (TGWS) by Tran, B, Dancey, J, Kamel-Reid, S, McPherson, J.D, Stein, L, Petrocelli, T, Shaw, P, Siu, L.L

Get full text

6604 POSTER Updated Survival and Genomic Analysis of a Phase II Trial of Temsirolimus in Advanced Neuroendocrine Carcinomas by Chau, N.G, Kamel-Reid, S, Zhang, T, Kindler, H, Saltz, L, Hirte, H, Kocha, W, Goss, G, Wang, L, Siu, L.L

Get full text

87INCARDIAC TOXICITY OF NOVEL AGENTS by Siu, L.L.

“…Abstract With the emergence of novel molecularly targeted agents and immunotherapeutics, cardiac and cardiovascular toxicities may occur as a consequence of…”
Get full text